The December 6th webinar has been recorded. Members of Société can view the webinar here
WEBINAR: New Cell Therapies: Patient Promise and Supply Chain Challenges
Cell therapies hold tremendous promise for patients. By using living cells as a drug to fight disease, such as cancer and immunological disorders, cell therapies utilize a patient’s own immune systems to target and destroy diseased cells in the body. Since the 1960’s, bone marrow transplants, which utilize healthy bone marrow cells to replace nonfunctioning ones, have been used with some success to treat several leukemias and as adjunct therapy to radiation treatment, and aplastic and sickle cell anemias. More recently, there have been a number of studies utilizing modified cells, including chimeric antigen receptor (CAR) T-cells, as therapies for treating patients with hematological cancers, as well as eye, autoimmune, and neurogenerative diseases. Clinical outcomes have been very promising and had high rates of therapeutic efficacy.
However, even as cell therapies are being developed as effective treatments for patients in need, there are a number of challenges still to address, including better ways to match the most effective treatment to the right patient, immune tolerance, supply chain complexities, manufacturing costs, and market access issues. Today there are over 100 companies active in developing new cell therapies utilizing a variety of approaches and addressing the various bottlenecks. As solutions to these challenges are addressed and a more favorable regulatory and insurance landscape evolves, the future is bright for getting new cell therapies to patients.
In our panel we will discuss the promise of cell therapies, the current state of the art, the challenges of getting the therapies to market, and future directions.
Note: Location for the December 6 event:
Société has moved to a new venue for the monthly meetings, a modern conference center near Bryant Park. The Jay Conference Center is located at 109 W 39th St, New York, NY 10018, a short walking distance from both Penn Station and Grand Central Station.
Option to attend virtually is now available. Unlimited slots available for virtual participation. Once you register for the virtual option, the link will be emailed to participants the day prior to the event.
Speakers:
|
|
 |
|
 |
David Hilbert, PhD
Founder and Former CEO,
Arcellx |
|
Adrian Rawcliffe
CEO,
Adaptimmune
Therapeutics PLC |
|
Moderator:
Paul Pospisil, PhD
Senior Client Partner,
Korn Ferry |
About our Speakers:
David Hilbert has spent the past 20+ years combining his disciplined approach to science with the business of effective drug development and corporate management. Dr. Hilbert was the founder and previous President and CEO of Arcellx, Inc., a company focused on the development of regulated immune cell therapies for treatment of human disease. From 2009-2014, Dr. Hilbert was the CSO at Zyngenia, Inc., and led the company’s development of multi-specific antibody-based therapeutics. From 2006 to 2009, Dr. Hilbert consulted with leading scientists, executives, and venture firms in assisting startup biotech companies with the many strategic and operational challenges associated with early stage drug development. In 2004, he served as Vice President of Research at Cellective Therapeutics, a start-up antibody company acquired by MedImmune in October 2005. Dr. Hilbert began his biotech career in 1996 at Human Genome Sciences (HGS) where he spent 8 years guiding the preclinical development of antibodies and genomics-based therapeutics.
Adrian “Ad” Rawcliffe has served as Chief Executive Officer of Adaptimmune Therapeutics PLC since September 2019 and is a member of the Executive Team. Previously, he served as the Chief Financial Officer from March 2015 through September 2019. Mr. Rawcliffe has over 20 years of experience within the biopharmaceutical industry and most recently served as Senior Vice President, Finance of GSK’s North American Pharmaceuticals business. He joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK’s Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK’s venture capital business. Mr. Rawcliffe currently serves as a non executive director of WAVE Life Sciences (NASDAQ:WVE). Mr. Rawcliffe qualified as a chartered accountant with PwC and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.
Paul Pospisil Ph.D. is a Senior Client Partner in Korn Ferry's New York office. He is a member of the Firm's Global Life Sciences Market specializing in the Biotechnology and Pharmaceuticals Sectors. Mr. Pospisil's primary focus is to assist biotechnology and biopharmaceutical companies in recruiting for positions such as chief executive officer, chief business officer, head of research and development and other key executives.
With over fifteen years prior experience in the industry as a successful executive and investor, Mr. Pospisil brings a thoughtful perspective to executive search, shaped by a breadth of experiences in new product development, business development, financings, strategy, company building, operational leadership and board functions from start-up, growth to mature biotechnology and biopharmaceutical companies.
Prior to joining Korn Ferry, Mr. Pospisil was a co-founder and managing partner of both Aduro Capital LLC, an investment management company focused on the public healthcare sector and Aduro Partners LLC, an advisory firm focused on helping venture-backed and public life science companies assess, evaluate, partner opportunities and build businesses. Previously, he was a partner in life science investments at Atlas Venture and earlier was with Millennium Pharmaceuticals, where his last position was director, strategy leadership. Earlier, he was a new product manager at Altus Biologics, a spin-out of Vertex Pharmaceuticals. Mr. Pospisil holds a doctor of philosophy in organic chemistry from Harvard University and a bachelor's degree in biochemistry from New York University. He also attended Harvard Business School's Program for Management Development (PMD).